drugset / Trial / NCT03319953
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to antipsychotics in participants with stable schizophrenia.
Timeline
- Start
- 2017-12-21
- Primary completion
- 2019-09-11
- Completion
- 2019-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZELATRIAZIN | Small molecule | 40 mg | Oral |
| Subject | ZELATRIAZIN | Small molecule | 160 mg | Oral |
| Background | Asenapine | Other / unclassified | — | — |
| Background | Iloperidone | Small molecule | — | — |
| Background | Lurasidone | Small molecule | — | — |
| Background | Olanzapine | Small molecule | — | — |
| Background | Paliperidone | Unknown | — | — |
| Background | Quetiapine | Small molecule | — | — |
| Background | Risperidone | Other / unclassified | — | — |
| Background | Ziprasidone | Small molecule | — | — |